SEC 13F Intelligence

Managers / Q2 2024 · view latest →

ABG-WTT Global Life Science Capital Partners GP Ltd

CIK 0001832108 · SUITE 3902, 39/F, EAST TOWER, CHEUNG KONG CNTR II, 10 HARCOURT ROAD, CENTRAL, HONG KONG, K3, 000000 · 852 31219699

Reported Value
$30M
Q2 2024
Positions
3
Filings on Record
22
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Abg-Wtt Global Life Science Capital Partners GP Ltd reported $30M in U.S.-listed holdings across 3 positions for Q2 2024.

The portfolio is heavily concentrated: CGON alone accounts for 96.4% of reported value.

The book was largely unchanged from Q1 2024.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Largest Position
+96.4%
Cg Oncology

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $115MQ4 ’20Q1 ’21: $92MQ2 ’21: $52MQ3 ’21: $15MQ3 ’21Q4 ’21: $7MQ1 ’22: $12MQ2 ’22: $28MQ2 ’22Q3 ’22: $16MQ4 ’22: $6MQ1 ’23: $6MQ1 ’23Q2 ’23: $6MQ3 ’23: $21MQ4 ’23: $51MQ4 ’23Q1 ’24: $42MQ2 ’24: $30MQ3 ’24: $20MQ3 ’24Q4 ’24: $44MQ1 ’25: $38MQ2 ’25: $27MQ2 ’25Q3 ’25: $19MQ4 ’25: $15MQ1 ’26: $12MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $30M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CGONCG ONCOLOGY INCHELD+0915.5K−$11M$29M
LUNGPULMONX CORPHELD+060.2K−$176,398$381,693
RPIDRAPID MICRO BIOSYSTEMS INCHELD+01.04M−$83,064$685,275

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

3 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CGONCG ONCOLOGY INChistory →COM96.44%$29M915.5K
2RPIDRAPID MICRO BIOSYSTEMS INChistory →CLASS A COM2.29%$685,2751.04M
3LUNGPULMONX CORPhistory →COM1.27%$381,69360.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$12M2May 18, 202613F-HRchanges · EDGAR ↗
Q4 2025$15M2Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$19M2Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$27M2Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$38M4May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$44M4Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$20M3Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$30M3Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$42M3May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$51M4Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$21M4Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$6M3Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$6M3May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$6M3Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$16M3Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$28M3Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$12M3May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$7M2Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$15M2Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$52M2Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$92M2May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$115M2Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.